Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd. ("Tikva"), a biotechnology company...
Hence then, the article about tikva allocell closes 8 million series a financing to advance engineered ebv specific t cell therapy for solid tumors was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors )
Also on site :
- Black Friday in July? Macy’s Drops Dozens of Summertime Deals, From Under-$100 Tech to Trendy Band Tees
- Walmart’s ‘Vibrant’ $40 Floral Area Rug Is Machine-Washable, Pet-Friendly, and Full of Cottagecore Charm
- Martha Stewart’s ‘Elegant’ and Modern Wooden Desk Is ‘Just the Right Size’ and It’s Now Under $200 at Amazon